Metabolic Syndrome, C-Reactive Protein, and Chronic Kidney Disease in Nondiabetic, Nonhypertensive Adults

American Journal of Hypertension

Volumn 20, Issue 11, 2007, Pages 1189-1194

  Lee, Jung Eun ^a   Choi, So Yeon ^a   Huh, Wooseong ^a   Kim, Yoon Goo ^a   Kim, Dae Joong ^a   Oh, Ha Young ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

C reactive protein; Chronic kidney disease; metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL OBESITY; ADULT; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHRONIC DISEASE; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; KOREA; MALE; MASS SCREENING; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; ODDS RATIO; TRIGLYCERIDES;

EID: 35348910680     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.04.020     Document Type: Article

References (30)

1. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
2. Sarafidis P.A., and Bakris G.L. Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant 21 (2006) 2366-2374
3. Segura J., and Ruilope L.M. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. Fundam Clin Pharmacol 19 (2005) 429-437
4. Fox C.S., Larson M.G., Leip E.P., Culleton B., Wilson P.W., and Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA 291 (2004) 844-850
5. Chen J., Muntner P., Hamm L.L., Jones D.W., Batuman V., Fonseca V., Whelton P.K., and He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140 (2004) 167-174
6. Kurella M., Lo J.C., and Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16 (2005) 2134-2140
7. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
8. Festa A., D'Agostino Jr. R., Howard G., Mykkanen L., Tracy R.P., and Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102 (2000) 42-47
9. Haffner S.M. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 97 (2006) 3A-11A
10. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107 (2003) 391-397
11. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino Sr. R.B., and Wilson P.W. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 (2004) 380-385
12. Malik S., Wong N.D., Franklin S., Pio J., Fairchild C., and Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 28 (2005) 690-693
13. Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D.S., Haffner S.M., Isles C., Macfarlane P.W., Packard C.J., Cobbe S.M., and Shepherd J. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108 (2003) 414-419
14. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., Tylavsky F.A., and Newman A.B. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292 (2004) 2237-2242
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S1-S266
16. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., Kitzmiller J., Knowler W.C., Lebovitz H., Lernmark A., Nathan D., Palmer J., Rizza R., Saudek C., Shaw J., Steffes M., Stern M., Tuomilehto J., and Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
17. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith Jr. S.C., Spertus J.A., and Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
18. Rader D.J. Inflammatory markers of coronary risk. N Engl J Med 343 (2000) 1179-1182
19. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith Jr. S.C., Taubert K., Tracy R.P., and Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
20. Beddhu S., Kimmel P.L., Ramkumar N., and Cheung A.K. Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 46 (2005) 577-586
21. Stuveling E.M., Hillege H.L., Bakker S.J., Gans R.O., De Jong P.E., and De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 63 (2003) 654-661
22. Yeun J.Y., Levine R.A., Mantadilok V., and Kaysen G.A. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35 (2000) 469-476
23. Tripepi G., Mallamaci F., and Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16 Suppl 1 (2005) S83-S88
24. Kaysen G.A. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12 (2001) 1549-1557
25. Becker B., Kronenberg F., Kielstein J.T., Haller H., Morath C., Ritz E., Fliser D., and MMKD study group. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 16 (2005) 1091-1098
26. Hall J.E., Brands M.W., and Henegar J.R. Mechanisms of hypertension and kidney disease in obesity. Ann N Y Acad Sci 892 (1999) 91-107
27. Locatelli F., Pozzoni P., and Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 17 (2006) S81-S85
28. Iseki K., Ikemiya Y., Kinjo K., Inoue T., Iseki C., and Takishita S. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65 (2004) 1870-1876
29. Ejerblad E., Fored C.M., Lindblad P., Fryzek J., McLaughlin J.K., and Nyren O. Obesity and risk for chronic renal failure. J Am Soc Nephrol 17 (2006) 1695-1702
30. Molitch M.E., DeFronzo R.A., Franz M.J., Keane W.F., Mogensen C.E., and Parving H.H. Diabetic nephropathy. Diabetes Care 26 Suppl 1 (2003) S94-S98